CJC-1295

• GHRH receptor binding and pituitary GH stimulation activating GHRH-R on the anterior pituitary to stimulate GH release in a pattern that closely mimics the body's natural secretion, preserving pulsatility rather than creating a flat sustained elevation
• DAC albumin binding for extended half-life with the Drug Affinity Complex providing a lysine linker that enables covalent binding to serum albumin, protecting the peptide from enzymatic degradation and extending active plasma half-life to approximately 6 to 8 days from the approximately 30 minutes seen without DAC
• IGF-1 elevation downstream of GH release with increased GH output stimulating hepatic IGF-1 production, the primary mediator of GH's anabolic effects on muscle, bone, and connective tissue
• Preserved GH pulsatility with DAC with research demonstrating that despite the extended half-life, natural pulsatile GH secretion is maintained rather than replaced by flat continuous stimulation
• Synergistic GH axis amplification with GHRPs with CJC-1295 acting on the GHRH pathway while compounds like ipamorelin act on the ghrelin receptor pathway, combining to produce significantly greater GH release than either alone

CJC-1295 (both forms) is studied for

• Increased muscle mass and protein synthesis driven by elevated GH and IGF-1 creating an anabolic environment that supports muscle growth and recovery beyond what training alone produces
• Enhanced fat metabolism and body composition with GH directly stimulating lipolysis and preferential oxidation of stored fat, particularly visceral fat, during sustained elevation
• Improved recovery and tissue repair through IGF-1 and GH activity in muscle, tendon, and connective tissue, shortening recovery windows and supporting repair following intense training
• Skin and hair quality improvement consistent with the broad tissue maintenance effects of optimized GH and IGF-1 signaling across epithelial and connective tissue
• Physiological GH stimulation without suppressing endogenous production preserving the body's natural feedback mechanisms rather than replacing them, distinguishing GHRH analog use from direct GH administration

Reported findings in research include

• Water retention particularly with the DAC version due to sustained GH elevation, which can cause puffiness and temporary scale weight increases
• Elevated blood glucose a meaningful metabolic consideration as GH has counter-regulatory effects on insulin signaling; monitoring fasting glucose during use is advisable
• Numbness and tingling reported by some users, consistent with fluid shifts and nerve compression associated with GH elevation and water retention
• Changes in appetite possible in both directions depending on individual response to GH axis stimulation
• Greater side effect risk with DAC due to continuous stimulation versus the more physiological pulsatile pattern produced by the No DAC version dosed daily

Common synergistic combinations studied in research models: With CJC-1295 No DAC: With CJC-1295 With DAC: No negative interactions between CJC variants and other GH secretagogues have been documented in controlled preclinical systems, but GH axis overstimulation is a monitored area in research.

• GHRP-2
• GHRP-6
• Ipamorelin
• Tesamorelin (separate pathway)
• Often used alone due to already strong GH elevation
• Stacked cautiously with GHRPs in metabolic or body-composition models